NEW YORK (GenomeWeb News) – Sangamo BioSciences today said that it has licensed to Pfizer the use of certain zinc finger protein nuclease reagents for use in clinical and commercial production of therapeutic proteins.
 
The Richmond, Calif.-based firm said that it had licensed to Pfizer non-exclusive, worldwide rights to use the reagents to permanently eliminate the glutamine synthetase gene in Chinese Hamster Ovary cell lines. The cells will be used for producing the therapeutic proteins.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new report highlights the potential threats posed by advances in synthetic biology, NPR reports.

A Bloomberg reporter tried to get her genetic data deleted, but found it's not so simple to do.

Johns Hopkins University's Steven Salzberg and his colleagues have come up with a new estimate for the number of human genes, Nature News reports.

In Genome Research this week: study of intra-tumor heterogeneity, workflow resources for EPIGEN-Brazil, and more.